Beijing is set to expand a programme that administers experimental coronavirus vaccines as Chinese developers chart a risky path to dominating global supplies.
In a surprise announcement last month, a representative from state-owned China National Biotec Group, or Sinopharm, revealed that hundreds of thousands of Chinese had already taken the company’s two leading experimental Covid-19 vaccines.
The drugs were dispensed as part of a limited use programme that began with little fanfare by the Chinese government in July. The vaccines were administered even though final stage, or phase 3, trials designed to confirm overall effectiveness had not been completed.
您已阅读12%（663字），剩余88%（4728字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。